154673-64-0Relevant academic research and scientific papers
Si-directed regiocontrol in asymmetric Pd-catalyzed allylic alkylations using C1-ammonium enolate nucleophiles
Fyfe, James W.B.,Kabia, Omaru M.,Pearson, Colin M.,Snaddon, Thomas N.
, p. 5383 - 5391 (2018)
Cooperative catalysis enables the direct enantioselective α-allylation of linear prochiral esters using Si-substituted allyl electrophiles. The Si-substituent directs the regioselectivity of enantioselective bond formation and provides products containing synthetically versatile pentafluorophenyl ester and vinylsilane moieties. Critical to the efficacy of this process was the recognition that the ancillary ligand on palladium could be altered to prevent formation of a deleterious ether by-product, whilst retaining enantioselectivity through the Lewis base catalyst. Flexibility such as this is unique to cooperative catalysis events and provides efficient access to an array of enantioenriched products that are orthogonally functionalized and easily modified.
New deoxynojirimycin derivatives as potent inhibitors of intestinal α-glucohydrolases
Lesur, Brigitte,Ducep, Jean-Bernard,Lalloz, Marie-Noelle,Ehrhard, Anne,Danzin, Charles
, p. 355 - 360 (2007/10/03)
New N-alkyl, alkenyl and benzyl substituted DNJ derivatives incorporating a silicon atom in the substituent were synthesised. Kinetic parameters (K(i), t( 1/4 )) for inhibition of rat intestinal α-glucohydrolases as well as human lysosomal α-glucosidases
N-derivatives of 1-deoxy nojirimycin
-
, (2008/06/13)
This invention relates to novel N-derivatives of 1-deoxy nojirimycin, to the method for their preparation and to their use in the treatment of diabetes and the use against retro-viruses, particularly in the treatment of acquired immuno-deficiency syndrome
N-derivatives of 1-deoxy nojirimycin
-
, (2008/06/13)
This invention relates to novel N-derivatives of 1-deoxy nojirimycin, to the method for their preparation and to their use in the treatment of diabetes and the use against retro-viruses, particularly in the treatment of acquired immuno-deficiency syndrome
